Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023.

Autor: Ringborg U; European Academy of Cancer Sciences, Stockholm, Sweden.; Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden., von Braun J; Pontifical Academy of Sciences, Vatican City, Italy.; Bonn University, Germany., Celis J; European Academy of Cancer Sciences, Stockholm, Sweden.; Danish Cancer Institute, Copenhagen, Denmark., Baumann M; European Academy of Cancer Sciences, Stockholm, Sweden.; German Cancer Research Center, Heidelberg, Germany., Berns A; European Academy of Cancer Sciences, Stockholm, Sweden.; The Netherlands Cancer Institute, Amsterdam, The Netherlands., Eggermont A; European Academy of Cancer Sciences, Stockholm, Sweden.; University Medical Center Utrecht & Princess Máxima Center for Pediatric Oncology, The Netherlands., Heard E; Pontifical Academy of Sciences, Vatican City, Italy.; European Molecular Biology Laboratory, Heidelberg, Germany., Heitor M; European Academy of Cancer Sciences, Stockholm, Sweden.; Centre for Innovation, Tech. & Policy Research, IN+@IS Tecnico, University of Lisbon, Portugal., Chandy M; Tata Medical Center, Kolkata, India.; Christian Medical College and Hospital, Vellore, India., Chen CJ; Pontifical Academy of Sciences, Vatican City, Italy.; Academia Sinica, Taipei, Taiwan., Costa A; European Academy of Cancer Sciences, Stockholm, Sweden.; European Commission, Cabinet of Commissioner Stella Kyriakides, Brussels, Belgium., De Lorenzo F; European Academy of Cancer Sciences, Stockholm, Sweden.; European Cancer Patient Coalition, Brussels, Belgium., De Robertis EM; Pontifical Academy of Sciences, Vatican City, Italy.; University of California, Los Angeles, CA, USA., Dubee FC; Beijing Genomics Institute (BGI), Helsinki, Finland., Ernberg I; Karolinska Institutet, Stockholm, Sweden., Gabriel M; European Commissioner for Innovation, Research, Culture, Education and Youth, Brussels, Belgium., Helland Å; Division for Cancer Medicine, Oslo University Hospital, Norway., Henrique R; Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Portugal., Jönsson B; European Academy of Cancer Sciences, Stockholm, Sweden.; Stockholm School of Economics, Sweden., Kallioniemi O; European Academy of Cancer Sciences, Stockholm, Sweden.; Science for Life Laboratory, Stockholm, Sweden., Korbel J; European Academy of Cancer Sciences, Stockholm, Sweden.; German Cancer Research Center, Heidelberg, Germany.; European Molecular Biology Laboratory, Heidelberg, Germany., Krause M; European Academy of Cancer Sciences, Stockholm, Sweden.; Carl Gustav Carus University Hospital and Faculty of Medicine, TU Dresden, Germany., Lowy DR; National Cancer Institute, Bethesda, MD, USA., Michielin O; CHUV Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Nagy P; European Academy of Cancer Sciences, Stockholm, Sweden.; Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary.; Department of Anatomy and Histology, HUN-REN-UVMB Laboratory of Redox Biology Research Group, University of Veterinary Medicine, Budapest, Hungary.; Chemistry Institute, University of Debrecen, Hungary., Oberst S; Organisation of European Cancer Institutes, Brussels, Belgium., Paglia V; Pontifical Academy for Life, Rome, Italy., Parker MI; University of Cape Town and African Academy of Sciences, South Africa., Ryan K; European Academy of Cancer Sciences, Stockholm, Sweden.; Cancer Research UK Scotland Institute, Glasgow, UK., Sawyers CL; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Schüz J; European Academy of Cancer Sciences, Stockholm, Sweden.; International Agency for Research on Cancer, Lyon, France.; World Health Organisation, Lyon, France., Silkaitis K; European Molecular Biology Laboratory, Heidelberg, Germany., Solary E; European Academy of Cancer Sciences, Stockholm, Sweden.; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France., Thomas D; Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Sydney, Australia., Turkson P; Pontifical Academy of Sciences, Vatican City, Italy., Weiderpass E; European Academy of Cancer Sciences, Stockholm, Sweden.; International Agency for Research on Cancer, Lyon, France.; World Health Organisation, Lyon, France., Yang H; Beijing Genomics Institute (BGI), Shenzhen, China.
Jazyk: angličtina
Zdroj: Molecular oncology [Mol Oncol] 2024 Feb; Vol. 18 (2), pp. 245-279. Date of Electronic Publication: 2024 Jan 22.
DOI: 10.1002/1878-0261.13575
Abstrakt: Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic technological and biological research provides clinical and prevention opportunities that make their implementation into healthcare systems more complex, mainly due to the growth of Personalized/Precision Cancer Medicine (PCM). Initiatives like the USA-Cancer Moonshot and the EU-Mission on Cancer and Europe's Beating Cancer Plan are initiated to boost cancer prevention and therapeutics/care innovation and to mitigate present inequalities. The conference organized by the Pontifical Academy of Sciences in collaboration with the European Academy of Cancer Sciences discussed the inequality problem, dependent on the economic status of a country, the increasing demands for infrastructure supportive of innovative research and its implementation in healthcare and prevention programs. Establishing translational research defined as a coherent cancer research continuum is still a challenge. Research has to cover the entire continuum from basic to outcomes research for clinical and prevention modalities. Comprehensive Cancer Centres (CCCs) are of critical importance for integrating research innovations to preclinical and clinical research, as for ensuring state-of-the-art patient care within healthcare systems. International collaborative networks between CCCs are necessary to reach the critical mass of infrastructures and patients for PCM research, and for introducing prevention modalities and new treatments effectively. Outcomes and health economics research are required to assess the cost-effectiveness of new interventions, currently a missing element in the research portfolio. Data sharing and critical mass are essential for innovative research to develop PCM. Despite advances in cancer research, cancer incidence and prevalence is growing. Making cancer research infrastructures accessible for all patients, considering the increasing inequalities, requires science policy actions incentivizing research aimed at prevention and cancer therapeutics/care with an increased focus on patients' needs and cost-effective healthcare.
(© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
Databáze: MEDLINE
Externí odkaz: